Effects of Patiromer and Sodium Zirconium Cyclosilicate on Blood Pressure in Rats with Chronic Kidney Disease

Effects of Patiromer and Sodium Zirconium Cyclosilicate on Blood Pressure in Rats with Chronic Kidney Disease

Background Potassium-binders patiromer and sodium zirconium cyclosilicate (SZC) are approved to treat hyperkalaemia, which is frequently observed in chronic kidney disease (CKD). Elevated blood pressure (BP) is common in CKD, due in part to impaired sodium excretion. The effect of patiromer, which e...

Full description

Bibliographic Details
Main Authors:	Lingyun Li MD, PhD, Jeff Budden BSc, Carol Moreno Quinn PhD, David Bushinsky MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-02-01
Series:	Journal of Cardiovascular Pharmacology and Therapeutics
Online Access:	https://doi.org/10.1177/10742484241227580

Similar Items

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
by: Donna Zarzuela, PharmD, et al.
Published: (2021-01-01)

In-vitro study of lithium binding by sodium zirconium cyclosilicate (Lokelma®) or patiromer (Veltassa®)
by: David B. Liss, et al.
Published: (2021-11-01)

Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure
by: Jean‐Claude Tardif, et al.
Published: (2023-04-01)

Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia
by: Teruhiko Imamura, et al.
Published: (2022-12-01)

Sodium zirconium cyclosilicate and metabolic acidosis: Potential mechanisms and clinical consequences
by: Raul Fernandez-Prado, et al.
Published: (2023-02-01)

Radiopacity of Sodium Zirconium Cyclosilicate in Computed Tomography: a case of a patient with Hyperkalemia and kidney disease
by: Andrea Angioi, et al.
Published: (2023-12-01)

Sodium zirconium cyclosilicate pretreatment for formula in vitro reduces potassium intake in infants with chronic kidney disease
by: Boxuan Liu, et al.
Published: (2022-12-01)

Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease
by: Takashin Nakayama, et al.
Published: (2023-03-01)

Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate
by: Teruhiko Imamura, et al.
Published: (2022-11-01)

Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure
by: Teruhiko Imamura, et al.
Published: (2022-09-01)

Compatibility study of patiromer with juices/liquids and soft foods
by: Martin Khoeiklang, et al.
Published: (2023-08-01)

Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients
by: Lei Tian, et al.
Published: (2023-12-01)

Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia
by: Teruhiko Imamura, et al.
Published: (2021-11-01)

Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden
by: Kun Kim, et al.
Published: (2022-08-01)

Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
by: Hayato Fujioka, et al.
Published: (2023-11-01)

Successful Conversion from Conventional Potassium Binder to Sodium Zirconium Cyclosilicate in a Patient with Refractory Constipation
by: Teruhiko Imamura, et al.
Published: (2022-05-01)

Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study
by: Agiro A, et al.
Published: (2023-09-01)

Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model‐informed drug development case study
by: Lindsay E. Clegg, et al.
Published: (2024-02-01)

Sodium zirconium cyclosilicate (ZS-9) treatment in patients with serum potassium >6.5 mEq/L
by: Henrik Rasmussen
Published: (2015-09-01)

Constipation as a Drug-Related Adverse Effect in Patients with Hyperkalemia: Sodium Zirconium Cyclosilicate versus Conventional Potassium Binders
by: Yuki Hida, et al.
Published: (2023-09-01)

Evaluation of safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate in management of hyperkalaemia in China: a real-world study protocol
by: Jing Yang, et al.
Published: (2023-03-01)

Largest Experience of Safety and Efficacy of Patiromer in Solid Organ Transplant
by: Kendra Schnelle, PharmD, et al.
Published: (2020-09-01)

Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study
by: Michel Jadoul, et al.
Published: (2023-05-01)

Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials
by: Alpesh N. Amin, et al.
Published: (2019-12-01)

Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
by: Jonathan Slawik, et al.
Published: (2020-10-01)

Blood Pressure Treatment in Kidney Transplant Recipients—Can We Improve?
by: Mari O. Onsøien, et al.
Published: (2021-04-01)

A Rare Case of Patiromer Induced Hypercalcemia
by: Swetha Rani Kanduri, et al.
Published: (2021-08-01)

Sodium Hydrosulfide Treatment During Porcine Kidney Ex Vivo Perfusion and Transplantation
by: Thomas Agius, MS, et al.
Published: (2023-11-01)

Pharmacodynamic effects of the K+ binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats
by: Sai Prasad N. Iyer, et al.
Published: (2020-09-01)

Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain
by: Patricia de Sequera, et al.
Published: (2023-11-01)

Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study
by: W Frank Peacock, et al.
Published: (2023-06-01)

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients
by: Csaba P. Kovesdy, et al.
Published: (2019-02-01)

Loss of Endothelial Glycocalyx During Normothermic Machine Perfusion of Porcine Kidneys Irrespective of Pressure and Hematocrit
by: Tobias M. Huijink, MD, et al.
Published: (2023-08-01)

Fluctuation of Blood Pressure in a Patient With Pheochromocytoma
by: Yuichi Fujii, MD, PhD, et al.
Published: (2020-12-01)

Atherosclerosis and Intrarenal Resistance Index in Kidney Transplant Recipients
by: Niels T. Bloemendal, BSc, et al.
Published: (2023-02-01)

Kidney Function Decline in Young Adulthood and Subsequent 24-Hour Ambulatory Blood Pressure in Midlife: The CARDIA Study
by: Lama Ghazi, MD, PhD, et al.
Published: (2022-02-01)

Extract Alleviates Inflammation in Kidney and Liver of the 2-Kidney-1-Clip Hypertensive rat
by: Nattaya Thongsepee PhD, et al.
Published: (2024-04-01)

Regulatory T-cell Number in Peripheral Blood at 1 Year Posttransplant as Predictor of Long-term Kidney Graft Survival
by: David San Segundo, PhD, et al.
Published: (2019-03-01)

Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
by: Colbert G, et al.
Published: (2022-07-01)

Frailty and Kidney Transplantation: A Systematic Review and Meta-analysis
by: Evelien E. Quint, BSc, et al.
Published: (2021-06-01)